Original expectations of the Hancock valve and 20 years of clinical reality
- 1 January 1992
- journal article
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 6 (Supplement) , S75-S78
- https://doi.org/10.1093/ejcts/6.supplement_1.s75
Abstract
The standard (glutaraldehyde-preserved) Hancock porcine bioprosthesis was introduced into clinical practice in order to provide surgeons with a cardiac valve substitute which would be nonthrombogenic and therefore would not require anticoagulation, and would be durable, anatomically suitable, and noiseless. In the present report we have reviewed our long-term experience with Hancock porcine valve recipients in order to verify whether the original expectations of this bioprosthesis have been met.Keywords
This publication has 14 references indexed in Scilit:
- The Risk of Reoperation in Patients with Bioprosthetic ValvesJournal of Cardiac Surgery, 1991
- Influence of type of prosthesis on late results after combined mitral-aortic valve replacementThe Annals of Thoracic Surgery, 1991
- The Hancock II porcine bioprosthesisThe Journal of Thoracic and Cardiovascular Surgery, 1989
- Technical Considerations In Reoperation for Porcine Bioprosthetic Valve FailureJournal of Cardiac Surgery, 1988
- Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular OperationsThe Annals of Thoracic Surgery, 1988
- Emergency reoperation for primary tissue failure of porcine bioprosthesesThe American Journal of Cardiology, 1987
- Long-term Durability of the Hancock Porcine Bioprosthesis Following Combined Mitral and Aortic Valve Replacement: An 11-Year ExperienceThe Annals of Thoracic Surgery, 1987
- Isolated Mitral Valve Replacement with the Hancock Bioprosthesis: A 13-Year AppraisalThe Annals of Thoracic Surgery, 1984
- Pregnancy in patients with a porcine valve bioprosthesisThe American Journal of Cardiology, 1982
- Porcine valvesProgress in Cardiovascular Diseases, 1980